rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LXEO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Lexeo cardiomyopathy asset data prompts Street price target increases
      Nov 16Seeking AlphaLXEO
      Why Is Lexeo Therapeutics Stock Trading Higher Today? - Lexeo Therapeutics (NASDAQ:LXEO)
      Nov 16BenzingaLXEO
      Lexeo Therapeutics Q3 Earnings Call Highlights
      Nov 16Yahoo FinanceLXEO
      Lexeo Nov 2026 presentation: gene therapy shows 80% arrhythmia reduction
      Nov 16Investing.comLXEO
      Raymond James raises Lexeo Therapeutics price target on trial data
      Nov 16Investing.comLXEO
      Why is Lexeo Therapeutics stock surging today?
      Nov 16Investing.comLXEO
      Lexeo Therapeutics shares surge 25% on interim data for LX2020 gene therapy
      Nov 16Investing.comLXEO
      Lexeo Therapeutics stock gets Stifel buy rating on PKP2 data
      Nov 16Investing.comLXEOSF
      Lexeo reports interim trial results for PKP2-ACM gene therapy
      Nov 16Investing.comLXEO
      Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
      Nov 16Yahoo FinanceLXEO
      Oppenheimer reiterates Lexeo Therapeutics stock rating on trial data
      Nov 2Investing.comLXEO
      Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
      Nov 2Yahoo FinanceLXEO
      Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
      Oct 25Yahoo FinanceLXEO
      Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - Slideshow (NASDAQ:LXEO) 2026-10-24
      Oct 24Seeking AlphaLXEO
      Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
      Oct 24Yahoo FinanceLXEO
      Lexeo at Chardan healthcare conference: pipeline advances, cash runway
      Oct 20Investing.comLXEO
      Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
      Oct 19Yahoo FinanceLXEO
      Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
      Oct 8Yahoo FinanceLXEO
      Stifel reiterates Buy rating on Lexeo Therapeutics stock at $17
      Oct 5Investing.comLXEO
      Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

      Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study Presentation will include new mFARS subscore analyses providing additional insight into neurologic outcomes following LX2006 treatment NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on resha

      Oct 1Yahoo FinanceLXEO
      Lexeo Therapeutics at Stifel 2026 Virtual Cardiometabolic Forum: pipeline push
      Sep 30Investing.comLXEOSF
      Lexeo Therapeutics completes acquisition of Mantle Therapeutics
      Sep 29Investing.comLXEO
      Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX)

      Detailed price information for Lexeo Therapeutics Inc (LXEO-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailELDNEWTXLXEO
      Leerink Partners Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

      Detailed price information for Lexeo Therapeutics Inc (LXEO-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailLXEO
      Lexeo gains access to Apertura’s gene therapy capsid
      Sep 23Investing.comLXEO
      Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

      Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia. Apertura's TfR1 CapX is an intravenously delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1) and cross the blood-brain barrier.

      Sep 23Yahoo FinanceLXEO
      Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

      NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on

      Sep 23Yahoo FinanceLXEOSF
      Baird reiterates Lexeo Therapeutics stock rating on acquisition deal
      Sep 22Investing.comLXEO
      Why is Lexeo Therapeutics stock gaining today?
      Sep 22Investing.comLXEO
      Lexeo stock rises on $21.3M Mantle deal for FA therapies
      Sep 22Investing.comLXEO
      Raymond James reiterates Strong Buy on Lexeo stock after acquisition
      Sep 22Investing.comLXEORJF
      Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Telefona

      U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.

      Sep 22BenzingaERICLXEO
      Lexeo to acquire Mantle Therapeutics for $21.3M
      Sep 22Investing.comLXEO
      Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
      Sep 22Yahoo FinanceLXEO
      Lexeo Therapeutics to Acquire Mantle Therapeutics for Up to $21.3 Million; Enters Three Research Collaborations
      Sep 22Yahoo FinanceLXEO
      Lexeo Therapeutics at Cantor conference: gene therapy push gains traction
      Sep 10Investing.comLXEO
      Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

      NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026. Fireside chat on Wednesday, September 9, 2026 at 2:10 p.m. ET in New York, NY. Baird 2026 Global Healthcare Conference. Fireside chat on Tuesday, Sep

      Sep 2Yahoo FinanceLXEO

      This is the newest page. Registered accounts read further back.